Schedule 13D ownership disclosure
Avalo Therapeutics, Inc.
Security class unavailable · CUSIP: 05338F108
Event date: 2023-02-07
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 35.1000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001011438-23-000145
- Form type
- SC 13D
- Filer
- ARMISTICE CAPITAL, LLC
- CIK
- CIK 1601086
- Filed
- Feb 09, 2023
- Reporting period
- Feb 07, 2023
- Description
- Schedule 13D beneficial ownership